Abstract
Background Empirical evidence on the indirect herd benefits of COVID-19 vaccination and/or prior infection is limited. We aimed to examine how area-level immunity interacts with individual-level immunity to affect COVID-19 diagnoses and deaths.
Methods Ontario residents aged ≥18 years were followed from August-01-2021 to January-30-2022. Individual-level immunity was defined as received a primary series of COVID-19 vaccines or a positive SARS-CoV-2 test in the past 165 days. Area-level immunity was determined based on the proportion of immune individuals in an individual’s residing area. We used logistic regression and cause-specific hazard models to examine the relationship between immunity and COVID-19 diagnosis, and between immunity and COVID-19 death, respectively. We included an interaction term between individual-level and area-level immunity in each model.
Results Of 11,122,816 adults, 7,518,015 (67.6%) were immune at baseline. After accounting for individual-level demographics, baseline health, and area-level social determinants of health, area-level immunity (highest vs. lowest quintiles) was associated with lower odds of COVID-19 diagnosis; the association was larger among non-immune (odds ratios [95% confidence interval]: 0.72 [0.70, 0.75]) than immune individuals (0.93 [0.90, 0.96]). Higher area-level immunity (highest vs. lowest quintiles) was also associated with lower hazard of COVID-19 death among non-immune individuals (hazard ratio: 0.77 [0.60, 1.00]).
Conclusions Our study provides observational evidence supporting the herd benefits of vaccination or prior infection on SARS-CoV-2 infections and COVID-19 deaths. Findings reinforce the need for high vaccination coverage to protect vaccinated and unvaccinated populations, while providing insights for interpreting vaccine effectiveness estimates in the context of herd immunity.
Main points Using area-level immunity coverage as a proxy for herd immunity, our study demonstrates observational evidence of indirect herd benefits from vaccination and/or prior infection on SARS-CoV-2 infections and COVID-19 deaths. Moreover, herd benefits are greater among non-immune individuals.
Competing Interest Statement
Linwei Wang: No conflict of interest. Sarah Swayze: No conflict of interest. Arjumand Siddiqi: No conflict of interest. Stefan D. Baral: SDB participates in Health Canada related programming including vaccination, and COVID-19-related clinical work; and serves on the National Institutes of Health-funded data and safety monitoring boards (unpaid). Beate Sander: No conflict of interest. Hind Sbihi: no conflict of interest Jeffrey C. Kwong: No conflicts of interest. Sharmistha Mishra: No conflict of interest.
Funding Statement
Funding for this research came from the Canadian Institutes of Health Research (grant no. VR5-172683, VS1-175536, VS2-175581, GA1-177697). This study was also supported by ICES, which is funded by an annual grant from the MOH and the Ministry of Long-Term Care (MLTC). ICES is an independent, non-profit research institute whose legal status under Ontario health information privacy law allows it to collect and analyze health care and demographic data, without consent, for health system evaluation and improvement. This study was also supported by the Ontario Health Data Platform (OHDP), a Province of Ontario initiative to support Ontario ongoing response to COVID-19 and its related impacts. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by the OHDP, its partners, or the Province of Ontario is intended or should be inferred. The following authors are supported by Canada Research Chairs (CRC): SM (Tier 2 CRC in Mathematical Modelling and Program Science, CRC-950-232643); BS (Tier 1 CRC in Economics of Infectious Diseases, CRC-2022-00362). JK is supported by a Clinician-Scientist Award from the University of Toronto Department of Family and Community Medicine.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The use of the data in this project is authorized under section 45 of Ontario Personal Health Information Protection Act and does not require review by a Research Ethics Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Alternative contact author: Linwei Wang, MSc, MAP-Centre for Urban Health Solutions, St. Michael’s Hospital, Unity Health Toronto, University of Toronto, 209 Victoria St, Toronto, ON, Canada, M5B 1T8, E: linwei.wang{at}unityhealth.to T: 587-938-2391
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos